J Appl Ecol 2007, 44:302–311.CrossRef 49. Singh SV, Singh PK, Singh AV, Sohal JS, Gupta VK, Vihan VS: Comparative efficacy of an indigenous ‘inactivated vaccine’ using highly pathogenic field strain of Mycobacterium avium subspecies paratuberculosis ‘Bison type’ with a commercial vaccine for the control of Capri-paratuberculosis in India. Vaccine 2007, 25:7102–7110.CrossRefPubMed 50. Pavlik I, Horvathova A, Dvorska L, Bartl J, Svastova P, du Maine R, Rychlik I: Standardisation of restriction fragment length polymorphism
analysis for Mycobacterium avium subspecies paratuberculosis. J Microbiol Methods 1999, 38:155–167.CrossRefPubMed 51. MRI Mycobacteria Pulsed-Field Gel Electrophoresis Captisol nmr Database[http://www.moredun.ac.uk/PFGE-mycobacteria] 52. Selander RK, Caugant DA, Ochman H, Musser JM, Gilmour MN, Whittam TS: Methods of multilocus enzyme electrophoresis for bacterial population genetics and
systematics. Appl Environ Microbiol buy TPCA-1 1986, 51:873–884.PubMed 53. Mazars E, Lesjean S, Banuls AL, Gilbert M, Vincent V, Gicquel B, Tibayrenc M, Locht C, Supply P: High-resolution minisatellite-based typing as a portable approach to global analysis of Mycobacterium tuberculosis molecular epidemiology. Proc Natl Acad Sci USA 2001, 98:1901–1906.CrossRefPubMed 54. Hunter PR, Gaston MA: Numerical index of the discriminatory ability of typing systems: an application of Simpson’s Index of Diversity. J Clin Microbiol 1988, 26:2465–2466.PubMed 55. Grundmann H, Hori S, Tanner G: Determining confidence intervals when measuring genetic diversity and the discriminatory abilities of typing methods for microorganisms. J Clin Microbiol Interleukin-3 receptor 2001, 39:4190–4192.CrossRefPubMed 56. Thibault VC, Grayon M, Boschiroli ML, Hubbans C, Overduin P, Stevenson K, Gutierrez MC, Supply P, Biet F: New variable-number tandem-repeat markers for typing Mycobacterium avium subsp. paratuberculosis and M. avium strains: Comparison with IS 900 and IS 1245 restriction fragment length
polymorphism typing. J Clin Microbiol 2007, 45:2404–2410.CrossRefPubMed Authors’ contributions KS conceived of the study, participated in its design and coordination, collated and analysed the data and drafted the manuscript. JA, SD, ZD, KD, IH, LDJ, MK, LM, IP, VT, PW participated in the laboratory and field work. FB, IH, PW and RZ participated in analyzing the data. GFG, DB, JMS, AG participated in the RO4929097 clinical trial conception, design and coordination of the study. All authors read, criticized and approved the final manuscript.”
“Background Staphylococcus aureus is a versatile opportunistic pathogen that causes a variety of infections ranging from superficial skin infections to severe, invasive diseases such as bacteraemia and necrotising pneumonia [1]. Its success as a human pathogen is highlighted by the fact that despite the development of antibiotic therapy, the frequency of staphylococcal bacteraemias is increasing [2].